Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RVMD |
---|---|---|
09:32 ET | 2676 | 57.06 |
09:33 ET | 100 | 57.2 |
09:35 ET | 706 | 56.71 |
09:37 ET | 500 | 56.47 |
09:39 ET | 600 | 56.43 |
09:42 ET | 600 | 56.47 |
09:44 ET | 466 | 56.7086 |
09:48 ET | 100 | 56.39 |
09:50 ET | 2858 | 56.96 |
09:51 ET | 910 | 56.885 |
09:53 ET | 3212 | 56.835 |
09:55 ET | 5199 | 57.005 |
09:57 ET | 305 | 56.905 |
10:00 ET | 700 | 56.97 |
10:02 ET | 1098 | 56.99 |
10:04 ET | 1918 | 56.855 |
10:06 ET | 106029 | 56.87 |
10:08 ET | 1200 | 57.1 |
10:09 ET | 1700 | 57.25 |
10:11 ET | 868 | 57.07 |
10:13 ET | 4571 | 57.01 |
10:15 ET | 1196 | 57.055 |
10:18 ET | 2639 | 56.97 |
10:20 ET | 2324 | 57.05 |
10:22 ET | 4088 | 56.92 |
10:24 ET | 210 | 56.985 |
10:26 ET | 2818 | 56.835 |
10:27 ET | 720 | 56.97 |
10:29 ET | 700 | 56.965 |
10:31 ET | 228 | 56.95 |
10:33 ET | 1216 | 56.845 |
10:36 ET | 1251 | 56.95 |
10:38 ET | 1838 | 56.89 |
10:40 ET | 10769 | 56.905 |
10:42 ET | 700 | 56.945 |
10:44 ET | 2265 | 56.935 |
10:45 ET | 23138 | 57.1 |
10:47 ET | 9395 | 57.11 |
10:49 ET | 3155 | 57.01 |
10:51 ET | 200 | 56.97 |
10:54 ET | 200 | 56.93 |
10:56 ET | 695 | 56.9 |
10:58 ET | 500 | 56.89 |
11:00 ET | 400 | 56.9 |
11:02 ET | 1093 | 56.93 |
11:03 ET | 200 | 56.86 |
11:05 ET | 250 | 56.86 |
11:07 ET | 600 | 56.92 |
11:09 ET | 500 | 56.915 |
11:12 ET | 8519 | 57.03 |
11:14 ET | 26195 | 56.93 |
11:16 ET | 400 | 57.01 |
11:18 ET | 400 | 57 |
11:20 ET | 900 | 57.05 |
11:21 ET | 1602 | 56.98 |
11:25 ET | 1100 | 57.05 |
11:27 ET | 600 | 57.05 |
11:30 ET | 30650 | 57.05 |
11:32 ET | 2158 | 57 |
11:34 ET | 700 | 56.99 |
11:36 ET | 1300 | 56.9 |
11:38 ET | 767 | 56.88 |
11:39 ET | 129545 | 57.25 |
11:41 ET | 1635 | 57.18 |
11:43 ET | 586 | 57.2 |
11:45 ET | 300 | 57.19 |
11:48 ET | 107 | 57.23 |
11:52 ET | 400 | 57.19 |
11:54 ET | 2625 | 57.17 |
11:56 ET | 1105 | 57.21 |
11:57 ET | 15535 | 57.255 |
11:59 ET | 400 | 57.315 |
12:01 ET | 1163 | 57.29 |
12:03 ET | 2111 | 57.27 |
12:06 ET | 400 | 57.3 |
12:08 ET | 8104 | 57.3 |
12:10 ET | 2238 | 57.4 |
12:12 ET | 1700 | 57.38 |
12:14 ET | 520 | 57.33 |
12:15 ET | 381 | 57.39 |
12:17 ET | 1367 | 57.39 |
12:19 ET | 625 | 57.39 |
12:24 ET | 26020 | 57.39 |
12:26 ET | 2305 | 57.37 |
12:28 ET | 561 | 57.3 |
12:32 ET | 1252 | 57.1 |
12:33 ET | 4000 | 57.15 |
12:35 ET | 2582 | 57.16 |
12:37 ET | 899 | 57.18 |
12:39 ET | 642 | 57.19 |
12:42 ET | 409 | 57.15 |
12:44 ET | 347 | 57.2 |
12:46 ET | 342 | 57.175 |
12:50 ET | 140 | 57.1843 |
12:51 ET | 847 | 57.17 |
12:53 ET | 698 | 57.11 |
12:57 ET | 100 | 57.13 |
01:00 ET | 200 | 57.11 |
01:02 ET | 100 | 57.09 |
01:04 ET | 600 | 57.21 |
01:06 ET | 300 | 57.2 |
01:08 ET | 100 | 57.17 |
01:09 ET | 507 | 57.18 |
01:11 ET | 1100 | 57.21 |
01:13 ET | 200 | 57.25 |
01:15 ET | 1231 | 57.29 |
01:18 ET | 400 | 57.3 |
01:20 ET | 545 | 57.28 |
01:22 ET | 107 | 57.27 |
01:24 ET | 200 | 57.28 |
01:26 ET | 1035 | 57.28 |
01:27 ET | 224 | 57.275 |
01:29 ET | 400 | 57.23 |
01:31 ET | 614 | 57.1883 |
01:33 ET | 200 | 57.2 |
01:36 ET | 1100 | 57.26 |
01:38 ET | 7300 | 57.3 |
01:40 ET | 1016 | 57.14 |
01:42 ET | 1200 | 56.95 |
01:44 ET | 700 | 56.9 |
01:45 ET | 1827 | 56.85 |
01:47 ET | 600 | 56.89 |
01:49 ET | 1929 | 56.965 |
01:51 ET | 353 | 56.925 |
01:54 ET | 1260 | 56.9 |
01:56 ET | 200 | 56.9 |
01:58 ET | 400 | 56.99 |
02:00 ET | 1946 | 56.9 |
02:02 ET | 523 | 56.9999 |
02:03 ET | 2785 | 57 |
02:05 ET | 900 | 56.94 |
02:07 ET | 471 | 56.97 |
02:09 ET | 1178 | 57.015 |
02:12 ET | 1417 | 57 |
02:14 ET | 400 | 57.01 |
02:18 ET | 1331 | 57 |
02:20 ET | 400 | 56.975 |
02:21 ET | 536 | 56.94 |
02:23 ET | 100 | 56.95 |
02:30 ET | 969 | 56.98 |
02:32 ET | 100 | 56.98 |
02:34 ET | 3004 | 56.99 |
02:36 ET | 200 | 56.94 |
02:38 ET | 1042 | 56.95 |
02:39 ET | 1476 | 56.95 |
02:41 ET | 1168 | 56.885 |
02:43 ET | 300 | 56.875 |
02:45 ET | 400 | 56.87 |
02:48 ET | 3338 | 56.8 |
02:50 ET | 13770 | 56.75 |
02:52 ET | 1000 | 56.725 |
02:54 ET | 100 | 56.73 |
02:56 ET | 1000 | 56.75 |
02:57 ET | 2059 | 56.7 |
02:59 ET | 300 | 56.715 |
03:01 ET | 1921 | 56.6 |
03:03 ET | 1043 | 56.51 |
03:06 ET | 4688 | 56.48 |
03:08 ET | 1100 | 56.575 |
03:10 ET | 3231 | 56.55 |
03:12 ET | 600 | 56.545 |
03:14 ET | 1218 | 56.68 |
03:15 ET | 1125 | 56.715 |
03:17 ET | 700 | 56.79 |
03:19 ET | 1061 | 56.78 |
03:21 ET | 3363 | 56.795 |
03:24 ET | 4142 | 56.805 |
03:26 ET | 1566 | 56.85 |
03:28 ET | 1756 | 56.79 |
03:30 ET | 1210 | 56.71 |
03:32 ET | 2149 | 56.74 |
03:33 ET | 1485 | 56.865 |
03:35 ET | 1032 | 56.85 |
03:37 ET | 700 | 56.87 |
03:39 ET | 850 | 56.885 |
03:42 ET | 757 | 56.87 |
03:44 ET | 1200 | 56.76 |
03:46 ET | 200 | 56.67 |
03:48 ET | 2668 | 56.65 |
03:50 ET | 28029 | 56.57 |
03:51 ET | 12796 | 56.84 |
03:53 ET | 4047 | 56.95 |
03:55 ET | 28113 | 56.85 |
03:57 ET | 9909 | 56.8 |
04:00 ET | 213598 | 56.75 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Revolution Medicines Inc | 9.6B | -15.8x | --- |
Vaxcyte Inc | 11.0B | -19.5x | --- |
Madrigal Pharmaceuticals Inc | 7.2B | -13.9x | --- |
Intra-Cellular Therapies Inc | 9.1B | -99.7x | --- |
Ascendis Pharma A/S | 7.4B | -16.6x | --- |
Nuvalent Inc | 6.1B | -27.3x | --- |
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.6B |
---|---|
Revenue (TTM) | $742.0K |
Shares Outstanding | 168.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.40 |
EPS | $-3.59 |
Book Value | $11.09 |
P/E Ratio | -15.8x |
Price/Sales (TTM) | 12,872.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -88,409.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.